Abstracts tagged "Intervention"

Abstract Number: 1666 • ACR Convergence 2024
Preliminary Effects of a Fully-Remote Online Physical Activity Program Following Knee Replacement
Scott Jamieson¹, Jessica Unick², Kailyn Horn¹, Halle Prine¹, Chih-Hsiang Yang¹ and Christine Pellegrini¹, ¹University of South Carolina, Columbia, SC, ²Brown Alpert Medical School at Brown University, Providence, RI
Background/Purpose: After knee replacement (KR), most adults fail to meet recommended levels of physical activity. Virtual options to promote physical activity in clinical populations have…
Abstract Number: 1696 • ACR Convergence 2024
Comparison of Mycophenolate Mofetil Plus Methotrexate versus Cyclophosphamide with Sequential Azathioprine for Active Takayasu’s Arteritis: An Open-Label, Randomized-Controlled Trial
XIAOCHUAN SUN¹, Jing Li¹, Xinwang Duan², Liyun Zhang³, Dongyun Yao⁴, Jing Xue⁵, zhenbiao wu⁶, Yi Zhao⁷, Lijun Wu⁸, HONGFENG ZHANG⁹, MENGTAO LI¹, Xiaofeng Zeng¹⁰, Peter Merkel¹¹ and Xinping Tian¹², ¹Peking Union Medical College Hospital, Beijing, China, ²The Second Affiliated Hospital of Nanchang University, Nanchang, China (People's Republic), ³Shanxi Bethune Hosptial, Taiyuan, China (People's Republic), ⁴Jiaozuo People's Hospital, Jiaozuo, Henan, China (People's Republic), ⁵Second Affiliated Hospital,Zhejiang University School of Medcine, Hangzhou, China (People's Republic), ⁶Xijing Hospital, Fourth Military Medical University, Xi'an, China (People's Republic), ⁷Xuanwu Hospital, Beijing, China, ⁸People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China (People's Republic), ⁹The First Affiliated Hospital of Dalian Medical University, Dalian, ¹⁰Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: The management of Takayasu’s arteritis (TAK) is challenging for lack of large-scale, high-quality clinical trials. Cyclophosphamide (CYC) is a conventional first-line immunosuppressant but is…
Abstract Number: 1940 • ACR Convergence 2024
Timely Initiation of Steroid Sparing Therapy in Uveitis Patients – a Quality Improvement Initiative
Bibi Ayesha¹, Claudia Castiblanco², Clement Tagoe³, Sarah Baron² and Sharon Rikin², ¹Montefiore Medical Center, Metuchen, NJ, ²Montefiore Medical Center, Bronx, NY, ³Montefiore Medical Center, New York
Background/Purpose: Uveitis is the inflammation of the eye, which is third leading cause of preventable blindness in the United States. Corticosteroids are the first line…
Abstract Number: 0470 • ACR Convergence 2023
Educational Intervention to Increase Contraception Screening and Documentation for Reproductive-Aged Women Seen in an Academic Rheumatology Clinic
Caroline Siegel¹, Deanna Jannat-Khah¹, Avi Mikhaylov¹, Erika Abramson², Nancy Pan¹ and Lisa Sammaritano³, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Only one-third of reproductive-aged women with rheumatic disease (RD) are prescribed effective contraception, even if prescribed teratogenic medications (Talabi et al. Arthritis Care Res.…
Abstract Number: PP01 • ACR Convergence 2023
You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Living with a rheumatic condition comes with unique concerns specific to mental and social health like struggling with fatigue, anxiety, depression, and isolation, all…
Abstract Number: 1009 • ACR Convergence 2023
More Implementation Strategies Are Not Associated with Better Implementation Outcomes: Implementing the Lupus Patient Decision Aid
larry hearld, Jasvinder Singh and Mark Beasley, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To assess the association of the number of implementation strategies for a patient lupus decision aid (DA) with perceived implementation outcomes, and the moderating…
Abstract Number: 1012 • ACR Convergence 2023
Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial
Candace Feldman¹, Katherine Crum², Kaitlin Hanken³, Constance Fontanet⁴, Ellen Sears², Theresa Oduol², Seanna Vine², Juliana Mastrorilli², Gauri Bhatkhande², Julie Lauffenburger², Rebecca Oran⁵, Ted Robertson⁶, Wendy Wood⁷ and Niteesh Choudhry³, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Center for Healthcare Delivery Sciences and Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Darmouth Geisel School of Medicine, Hanover, NH, ⁵BCBS, Boston, MA, ⁶Ideas42, San Francisco, CA, ⁷USC, Los Angelos, CA
Background/Purpose: Adherence to urate-lowering therapy (ULT) reduces the incidence of debilitating gout flares. Providing a cue for a behavior, reinforcing the behavior with a reward,…
Abstract Number: 1090 • ACR Convergence 2023
Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center
Shelby Gomez¹, Trisha Ludwig¹, Katherine Hartkopf², Sancia Ferguson³, Lori Zemlicka⁴, Mindy Jones⁵ and Christie M. Bartels⁶, ¹UW Health Pharmacy, Madison, WI, ²Pharmacy Society of Wisconsin, Madison, WI, ³University of Wisconsin, Madison, WI, ⁴UW Health, Madison, WI, ⁵Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: We embedded a clinical pharmacist into our university rheumatology clinics beginning in June 2022 to improve patient experience and reduce provider burden based on…
Abstract Number: 1113 • ACR Convergence 2023
Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients
Amanuel Kehasse¹, Sayali Dhamne², Michael LaValley³, Jean Liew² and Tuhina Neogi⁴, ¹Boston Medical Center, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University School of Medicine, Boston, MA
Background/Purpose: The management of gout remains poor despite the availability of effective medications and recommendation of a treat-to-target treatment strategy using of urate-lowering therapy (ULT).…
Abstract Number: 1215 • ACR Convergence 2023
Efficacy of Pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Bayram Farisogullari¹, Eduardo Santos², Emma Dures³, Rinie Geenen⁴ and Pedro Machado⁵, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ³Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁴Utrecht University, Vorstenbosch, Netherlands, ⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: To identify the best evidence on the efficacy of pharmacological interventions in reducing fatigue in people with I-RMDs and to summarise their safety in…
Abstract Number: 1321 • ACR Convergence 2023
Effect of Subcutaneous Local Anaesthesia Prior to Intra-Articular Injection: An Open Label, Paired-group, Randomized Controlled Trial
Alan Shaji¹, Varun Dhir², Chandra Bhushan Prasad³, Shankar Naidu¹, Aman Sharma⁴, Shefali Sharma⁵, Babita Ghai¹ and Sanjay Jain¹, ¹PGIMER, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³Healthway Hospital, Goa, Zuarinagar, India, ⁴PGIMER, Chandigarh, India, Chandigarh, India, ⁵PGIMER< Chandigarh, Chandigarh, India
Background/Purpose: Intraarticular injections are commonly used both for diagnostic and therapeutic injections of glucocorticoids in patients with inflammatory arthritis. The procedural pain felt by patients…
Abstract Number: 1331 • ACR Convergence 2023
Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein¹, Marike Van der Leeden², Franktien Turkstra², Jos W.R. Twisk¹, Maarten Boers¹, Henriët van Middendorp³, Peter Weijs⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Reade Rheumatology Center, Amsterdam, Netherlands, ³Leiden University, Leiden, Netherlands, ⁴Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced 28-joint Disease…
Abstract Number: 1509 • ACR Convergence 2023
Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Gabriel Figueroa-Parra¹, Maria Cuellar-Gutierrez¹, Mariana Gonzalez-Trevino¹, Larry J. Prokop², M. Hassan Murad³ and Ali Duarte-Garcia⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ³Evidence-based Practice Center, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding…
Abstract Number: 1583 • ACR Convergence 2023
Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)
Chandra Bhushan Prasad¹, Varun Dhir², Ranjan Gupta³, Koshy Nithin Thomas⁴, Devarasetti phani kumar⁵, VENKATESH S PAI⁶, Avinash Jain⁷, Shankar Naidu⁸, Priya Saini⁸, Leishangthem Bidyalaxmi⁸, AASTHA KHULLAR⁸, Ramesh Manthri⁹, Shefali Sharma¹⁰, Aman Sharma¹¹, Amita Aggarwal⁴ and Sanjay Jain⁸, ¹Healthway Hospital, Goa, Zuarinagar, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³All India Institute of Medical Sciences, New Delhi, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁵Nizams Institute of Medical Sciences, Hyderabad, India, ⁶AIIMS RISHIKESH, Rishikesh, India, ⁷SMS Medical College, Lucknow, India, ⁸PGIMER, Chandigarh, India, ⁹Department of Clinical Immunology and Rheumatology, Nizams Institute of Medical Sciences, Hyderabad, India, ¹⁰PGIMER< Chandigarh, Chandigarh, India, ¹¹PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: Methotrexate (MTX), the anchor drug for rheumatoid arthritis (RA), has limited bioavailability above an oral dose of 15 mg. Split-dose oral MTX (morning, evening…
Abstract Number: 1610 • ACR Convergence 2023
Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial
Michael Gendreau¹, Andrea Chadwick², Lance McCracken³, David Williams⁴, Daniel Clauw⁵, Juan Luciano⁶, Yifei Dai⁷, Nicolette Vega⁸, Zunera Ghalib⁸, Kristen Guthrie⁸, Allison Kraus⁸, Michael Rosenbluth⁸, Jennifer Zomnir⁹, Dana Reddy¹⁰ and Lesley arnold¹¹, ¹Gendreau Consulting, LLC, Poway, CA, ²Department of Anesthesiology, Pain, and Perioperative Medicine, University of Kansas School of Medicine, Kansas City, KS, ³Department of Psychology, Uppsala University, Uppsala, Sweden, ⁴Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁶Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona, Barcelona, Spain, ⁷Swing Therapeutics, Gainesville, FL, ⁸Swing Therapeutics, San Francisco, CA, ⁹DelRicht Resesarch, Mckinney, TX, ¹⁰Curavit, Scarsdale, NY, ¹¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH
Background/Purpose: Acceptance and Commitment Therapy (ACT), a form of guideline-recommended Cognitive Behavioral Therapy (CBT), has been empirically validated as a non-drug treatment for fibromyalgia (FM).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].